Last reviewed · How we verify
A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib (REMoDL-B)
The aims of this study are: * To evaluate the benefits of the addition of bortezomib to standard rituximab with cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) therapy in Diffuse Large B-cell Lymphoma (DLBCL). * To determine whether molecular phenotype effects the benefits derived from the addition of bortezomib.
Details
| Lead sponsor | University Hospital Southampton NHS Foundation Trust |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 1132 |
| Start date | 2011-04 |
| Completion | 2015-06 |
Conditions
- Lymphoma, Large B-Cell, Diffuse
Interventions
- Intravenous
- Bortezomib
Primary outcomes
- Progression Free Survival — 2 years
Countries
Switzerland, United Kingdom